ELI LILLY AND COMPANY LTD

Their core work

Eli Lilly's UK subsidiary is a major pharmaceutical company that contributes deep drug development expertise, proprietary clinical data, and disease biology knowledge to large-scale European public-private research partnerships. Their H2020 involvement spans primarily IMI (Innovative Medicines Initiative) projects, where they bring industry-grade capabilities in biomarker discovery, clinical trial design, and translational safety science. They focus heavily on neurodegeneration (Alzheimer's, protein misfolding), diabetes (type 1, type 2, diabetic complications), and chronic pain — three therapeutic areas where Lilly has significant commercial pipelines. Their role is typically to provide clinical compound access, patient cohort data, and pharma-perspective validation within large academic-industry consortia.

What they specialise in

How they've shifted over time

In the early period (2015–2017), Lilly's H2020 focus was disease-centric: biomarker discovery in diabetes and neurodegeneration, adaptive regulatory pathways (ADAPT-SMART), and classical drug target validation (PHAGO, IMPRiND). From 2018 onward, a clear shift emerged toward data infrastructure and interoperability — projects like EHDEN, FAIRplus, and NEURONET reflect growing investment in health data standardization, federated networks, and FAIR principles. This evolution mirrors the broader pharma industry pivot from isolated clinical programs toward platform-based, data-driven drug development ecosystems.

Lilly is moving from contributing disease expertise to individual projects toward shaping the shared data infrastructure that underpins multi-stakeholder drug development across Europe.

How they like to work

Lilly exclusively participates as a consortium partner — zero projects as coordinator — which is typical for large pharma in IMI, where academic or SME partners usually lead while industry provides in-kind contributions (data, compounds, expertise). With 556 unique partners across 32 countries, they operate as a highly connected hub in European health research. Their consistent presence across multiple IMI portfolios (neurodegeneration, diabetes, pain) means they are a repeat collaborator for many academic medical centers and biotech SMEs, making them a reliable and well-networked industry partner.

An exceptionally broad network of 556 unique consortium partners spanning 32 countries, concentrated in Western Europe's top academic medical centers, biotech SMEs, and regulatory bodies. Their network density reflects heavy participation in IMI mega-consortia that routinely involve 30–50 partners each.

What sets them apart

As a top-10 global pharmaceutical company, Lilly brings something most academic or SME partners cannot: access to proprietary clinical trial data, validated compound libraries, and real-world regulatory experience from marketed drugs. Their simultaneous involvement in disease-focused projects (neurodegeneration, diabetes, pain) AND data infrastructure projects (EHDEN, FAIRplus) makes them a bridge between therapeutic science and the emerging European health data ecosystem. For consortium builders, partnering with Lilly signals credibility to regulators and payers while unlocking industry-grade clinical validation capabilities.

Highlights from their portfolio

• REGAIN
  Lilly's largest direct EC funding (€1.35M) — focused on gamma-secretase inhibitors for hearing regeneration, an unusual therapeutic area for a diabetes/neuro-focused pharma company.
• EHDEN
  Flagship European health data network mapping millions of patient records to OMOP/FAIR standards — positions Lilly at the center of Europe's real-world evidence infrastructure.
• IMI-PainCare
  Comprehensive pain research initiative spanning acute pain, chronic pain, endometriosis, and bladder pain syndrome with deep phenotyping and patient stratification — a strategic bet on an underserved therapeutic area.